zenocutuzumab 
GtoPdb Ligand ID: 13649
|
Synonyms: Bizengri® | MCLA-128 | PB4188 [3] | R040517 | zenocutuzumab-zbco
zenocutuzumab is an approved drug (FDA (2024))
Compound class:
Antibody
Comment: Zenocutuzumab (MCLA-128) is a humanized IgG1 bispecific anti-epidermal growth factor receptor 2/3 (HER2/HER3) monoclonal antibody [2-3]. It prevents binding of the ligand neuregulin 1 (NRG1) to HER3 and this suppresses HER2/HER3 dimerization, phosphorylation and downstream signalling [8]. Genetic NRG1 fusions have been identified as oncogenic drivers in a small number of tumour types [4,6]. Zenocutuzumab-mediated modulation inhibits signalling through the PI3K-AKT-mTOR pathway and reduces tumour cell growth and invasiveness. Low fucose glycoengineering enhances zenocutuzumab's antibody-dependent cellular cytotoxicity (ADCC) activity.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| Selectivity at catalytic receptors | ||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License